

1 **Title**

2 Heritability and polygenic load for combined anxiety and depression.

3 **Authors**

4 Fara Tabrizi*,¹, Dr. Jörgen Rosén², Hampus Grönvall¹, Victor Rahimzadeh William-Olsson¹, Dr.
5 Erik Arner³, Dr. Patrik KE Magnusson⁴, Dr. Camilla Palm⁵, Dr. Henrik Larsson^{4,6}, Dr. Alexander
6 Viktorin³, Jens Bernhardsson¹, Johanna Björkdahl¹, Dr. Billy Jansson¹, Dr. Örjan Sundin¹, Dr. Xuan
7 Zhou⁷, Dr. Doug Speed⁷, and Dr. Fredrik Åhs¹.

8 **Affiliations**

9 ¹ Department of Psychology and Social Work, Mid Sweden University

10 ² Department of Clinical Neuroscience, Karolinska Institute; ³ Department of Medicine,
11 Karolinska Institute; ⁴ Department of Medical Epidemiology and Biostatistics, Karolinska
12 Institute; ⁵ Swedish Twin Registry, Karolinska Institute

13 ⁶ School of Medical Sciences, Örebro University,

14 ⁷ Centre for Quantitative Genetics and Genomics, Aarhus University

15 *Corresponding author: fara.tabrizi@miun.se

16 Department of Psychology & Social Work, Mid Sweden University

17 Kunskapens vag 8

18 Ostersund

19 Room: P1517

20 Phone: +46 73 511 64 27

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68

Abstract

Anxiety and depression commonly occur together resulting in worse health outcomes than when they occur in isolation. We aimed to determine whether the genetic liability for combined anxiety and depression was greater than when anxiety or depression occurred alone. Data from 12,558 genotyped twins (ages 38-85) were analysed, including 1,986 complete monozygotic and 1,809 complete dizygotic pairs. Outcomes were prescription of antidepressant and anxiolytic drugs, as defined by the World Health Organization Anatomical Therapeutic Chemical Classification System (ATC) convention, for combined anxiety and depression ($n = 1054$), anxiety only ($n = 744$), and depression only ($n = 511$). Heritability of each outcome was estimated using twin modelling, and the influence of common genetic variation was assessed from polygenic scores (PGS) for depressive symptoms, anxiety, and 40 other traits. Heritability of combined anxiety and depression was 79% compared with 41% for anxiety and 50% for depression alone. The PGS for depressive symptoms likewise predicted more variation in combined anxiety and depression (adjusted odds ratio per SD PGS = 1.53, 95% CI = 1.43-1.63; $\Delta R^2 = .031$, $\Delta AUC = .044$) than the other outcomes, with nearly identical results when combined anxiety and depression was defined by International Classification of Diseases (ICD) diagnoses (adjusted odds ratio per SD PGS = 1.70, 95% CI = 1.53-1.90; $\Delta R^2 = .036$, $\Delta AUC = .051$). Individuals in the highest decile of PGS for depressive symptoms had over 5 times higher odds of being prescribed medication for combined anxiety and depression compared to those in the lowest decile. We conclude that genetic factors explain substantially more variation in combined anxiety and depression than anxiety or depression alone.

69 Anxiety- and mood disorders are the most commonly occurring psychiatric disorders in the
70 general population, with lifetime prevalence estimates of up to 33.7% and 14.7%, respectively
71 (1,2). Symptoms of these disorder categories most often occur together, as evident by nearly half
72 of adults with anxiety also reporting depressive symptoms(3) and two-thirds of patients with a
73 primary diagnosis of major depressive disorder (MDD) also displaying pathological levels of
74 anxiety (4–6). It is of importance to distinguish between combined anxiety-depression and
75 anxiety or depression occurring alone because the combination has worse health outcomes,
76 entails greater risk of suicide, and is more resistant to treatment (7–9). Despite being highly
77 debilitating and prevalent, the heritability of this phenotype combination is largely unknown.
78 Hence, in the current study we aimed to determine whether the genetic contribution to
79 combined anxiety and depression differs from depression or anxiety alone.

80

81 Meta-analyses report twin-heritability in the range of 30-50% for separate occurrences of
82 anxiety- and depressive disorders (10,11), indicating a moderate heritable component. Although
83 the shared heritability between these disorder categories is known to be large (12,13), twin-
84 studies on combined anxiety and depression are scarce. In a rare instance, Guffanti et al. (14)
85 estimated the heritability for sequential comorbidity of anxiety disorders and MDD in the range
86 of 53-57% using a relatively small sample of 545 high-risk participants from 65
87 multigenerational families. The findings by Guffanti et al. suggest that the combination of anxiety
88 and MDD might be more heritable than when each disorder occur alone, but the small sample
89 size together with the probable oversampling of cases warrants replication before firm
90 conclusions can be drawn.

91

92 Anxiety- and depressive disorders have also been predicted from polygenic scores (PGS)
93 that are based on genomic variations associated with phenotypes in independent discovery
94 samples (15). To date, anxiety PGSs explain about 0.5% of variance when predicting anxiety
95 disorders in independent cohorts (16,17), while depression PGSs explain 0.27-2.2% of variance

96 in depression (18,19). Tentative evidence further suggests that individuals with comorbid
97 anxiety have higher PGSs for a broad depression phenotype (odds ratio per *SD* PGS = 1.17)
98 compared to participants meeting only MDD criteria (20). These results have been corroborated
99 by recent findings, indicating that depression with comorbid anxiety, as defined by ICD codes, is
100 associated with higher polygenic load for several psychopathological traits in comparison with
101 depression without anxiety (21). Although these reports suggest increased genetic liability for
102 combined anxiety and depression compared to when anxiety or depression occur alone, the
103 limited number of studies and the differences in how cases have been ascertained, make
104 generalizable conclusions premature.

105
106 Electronic health-record based studies of genetic influences on anxiety and depressive
107 disorders commonly depend on diagnoses from specialist care. This could potentially induce a
108 bias in estimates of genetic liability as most individuals seeking treatment for anxiety or
109 depression initially consult a general practitioner in primary care, and often receive a drug
110 prescription from these practitioners without referral to a specialist. To include patients
111 seeking care for anxiety (*Anxiety-only*), depression (*Depression-only*), or both (*Combined anxiety*
112 and depression) from both primary and specialist care, we here used an algorithm to search the
113 Swedish Prescribed Drug Register for information about the symptoms for which drugs were
114 prescribed. This so-called dosage text is written by the GP and contains the main indication for
115 the drug prescription. To validate the ascertainment of cases, we compared which drug classes
116 were most commonly prescribed for each symptom category (*Anxiety-only*, *Depression-only*,
117 *Combined anxiety and depression*). In addition to symptom categories based on drug
118 prescription, outcome groups were also defined by International Classification of Diseases (ICD)
119 diagnoses that only included patients referred to specialist care. This allowed us to evaluate
120 whether genetic influences on outcome categories were dependent on the definition of cases
121 (ICD diagnoses vs. drug prescription information). Notably, the term combined here refers to
122 having been prescribed drugs for symptoms of anxiety and depression or diagnosed with a

123 depression and an anxiety diagnosis within a given time period without necessarily being
124 simultaneously present at any point in that time period (22).

125 For the purpose of this study, we constructed PGSs for 6 different traits focusing on anxiety,
126 depression, schizophrenia, and neuroticism, while also using 36 predefined PGSs from the
127 polygenic index repository (23). We then sought to understand how various PGSs could predict
128 categories of individuals prescribed medication for symptoms of anxiety, depression, or both.
129 This analysis could reveal whether a specific PGS shows an advantage in predicting symptom- or
130 disorder categories compared to other PGSs. It would also inform on whether one indication for
131 drug prescription (i.e., one symptom category) has more genetic liability over others. The
132 analyses were then repeated with outcomes defined by ICD diagnoses. By using a sample of
133 monozygotic and dizygotic twins from the Swedish Twin Registry, we could also determine if
134 there was a correspondence between genetic liability of outcomes estimated from PGSs and
135 heritability using classic twin modelling.

136 Another aim was to determine the effect of having extremely high or low PGSs on anxiety,
137 depression or combined anxiety and depression. We estimated risk carried by extreme PGSs by
138 comparing individuals in each decile with those in the lowest decile of the PGS distribution to
139 determine the utility of PGSs regarding risk stratification.

140

141

142

143

144

145

146

147

148

149

150 **Method**

151 **Study population**

152 STAGE and YATSS are population cohorts of Swedish twins born between 1959-1985 and
153 1986-1992, respectively, that are part of the Swedish Twin Registry (24,25). The STAGE study
154 invited 25,364 twins to donate saliva for genotyping in 2005-2006, and 6,218 twins from YATSS
155 were invited in 2013-2014. Genotyping was performed on the 650K Illumina Global Screening
156 Array BeadChip for both cohorts in 2017-2019, resulting in a final sample of 13,699 twins with
157 genotype data available for 12,792 individuals. STAGE responders were representative of the
158 Swedish population in terms of educational attainment and family background characteristics
159 (26).

160

161 **Measures**

162 ***Anxiety and Depression Outcomes***

163 We obtained drug prescription data for the entire study population from the Swedish
164 Prescribed Drug Register (27) through the Swedish Twin Registry (STR). We included N06AA
165 non-selective monoamine reuptake inhibitors, N06AB selective serotonin reuptake inhibitors
166 (SSRIs), N06AF monoamine oxidase inhibitors (non-selective), N06AG monoamine oxidase A
167 inhibitors, N06AX other antidepressants (which include certain selective serotonin and
168 noradrenaline reuptake inhibitors as well as other drugs), N05BA benzodiazepine derivatives,
169 N05BE azaspirodecanedione derivatives, R06A antihistamines for systemic use, C07AA beta
170 blocking agents (non-selective), and N03AX other antiepileptics (i.e., pregabalin) based on their
171 Anatomical Therapeutic Chemical code (ATC) (28). For the above-mentioned ATC-categories, we
172 employed an algorithm that searched through the prescription text, also known as the dosage
173 text, written by the prescribing physician. If the text included any of the words “worry”,
174 “anxiety”, “anxiety issues” (one word in Swedish “orosbesvär”), or “panic”, the drugs were
175 classified as prescribed for symptoms of anxiety. For depression, one of the words “depression”,
176 “depressive”, “dejection” (i.e., “nedstämdhet” in Swedish), or “mood-enhancing” had to be

177 included in the text. The text-searching algorithm resulted in two columns for each drug, one
178 column for symptoms of anxiety and one for symptoms of depression, where individuals were
179 coded as 1 or 0 based on if the drug had been prescribed with or without the relevant target
180 words. Those without prescriptions of the target drugs were coded as NA and included as
181 controls. All drug prescriptions were treated as life-time events and there was no distinction
182 made between individuals prescribed drugs for anxiety and depression simultaneously, meaning
183 the terms occurred in conjunction in the dosage text, or individuals prescribed medication for
184 anxiety on one occasion and depression on another, meaning that the terms occurred in two or
185 more separate dosage texts. Based on the results from the text-searching algorithm, we
186 classified individuals into one of four categories, (1) if the text mentioned both anxiety and
187 depression they were included in the symptom category Combined anxiety and depression; (2)
188 if the text mentioned anxiety, but not depression, participants were included in the category
189 Anxiety-only; (3) if the text mentioned depression, but not anxiety, they were included in the
190 category Depression-only; (4) if the text did not mention anxiety or depression they were
191 categorized as *Medication-only*. The last group was included as the target drugs can be
192 prescribed for other indications than anxiety or depression (e.g., otherwise unspecified sleep
193 disorder, premenstrual syndrome, or adjustment disorder) and physicians sometimes omit
194 stating the indication that the medication is prescribed for. These symptom categories were
195 used as outcomes in subsequent statistical analyses, controls comprised those not included in
196 any of these categories.

197 We also obtained diagnoses from the National Patient Register, which are assigned by an
198 attending physician based on the International Classification of Diseases, eighth revision (ICD-8)
199 (1969-1986), ninth revision (ICD-9) (1987-1996), or tenth revision (ICD-10) (1997-present).
200 Similar to drug prescriptions, diagnoses were defined as life-time events and treated as binary
201 variables. Participants were categorized in the depression diagnosis group if they had any
202 depression-related ICD code, including 3004 (ICD-8), 300E, 311 (ICD-9), and F32-F39 (ICD-10).
203 Anxiety diagnosis was defined as having at least one of the following codes, 300 (excluding 3003,

204 3004) (ICD8), 300 (excluding 300D, 300E) (ICD-9), and F40-41 (excluding F41.2), F44-45, F48
205 (ICD-10). The F41.2 code was excluded from the anxiety diagnosis group, since it refers to
206 having symptoms of both anxiety and depression, but where neither is clearly predominant.
207 Participants with an F41.2 code were grouped in a third category (combined depression and
208 anxiety diagnoses), which also included those that had both a depression-related and an anxiety-
209 related ICD code. These 3 groups (Combined anxiety and depression, Anxiety-only, Depression-
210 only) were used as separate outcomes in subsequent analyses, in which controls included
211 participants that neither had a diagnosis nor been prescribed any antidepressants or anxiolytic
212 drugs.

213

214 ***Polygenic Scores (PGS)***

215 A total of 42 PGSs were evaluated. Thirty-six of these came from the polygenic index (PGI)
216 repository, which contains scores derived from large-scale GWASs conducted in 23andMe, UK
217 Biobank (29), as well as other available datasets. For each phenotype, PGSs have been
218 constructed in 11 repository cohorts including the STR, with a leave-one-out approach to
219 distinguish the discovery sample from the target cohort. Hence, PGSs in STAGE and YATSS were
220 created from GWAS summary statistics that exclude these datasets, which allows for unbiased
221 targeting of phenotypes in our sample to test the predictive performance of PGSs from the PGI-
222 repository. Information on quality control and PGS construction have been reported in detail
223 elsewhere (23).

224 In addition to the 36 PGSs from the PGI-repository, we constructed 6 PGSs based on
225 Lifetime Anxiety Disorder diagnosis (LAD; cases = 31977; controls = 82114), Major Depressive
226 Disorder (MDD; cases = 170756; controls = 329443), schizophrenia (SCZ; cases = 67390;
227 controls = 94015), Neuroticism scores (NEURO; $n = 323415$), the Generalized Anxiety Disorder
228 7-item scale (GAD-7; $n = 126175$), and the Patient Health Questionnaire-9 (PHQ-9; $n = 126733$).
229 The LAD-PGS was based on summary statistics from the meta-analysis performed by Purves et
230 al. (17), the MDD-PGS was based on summary statistics published in Wray et al. (19) and

231 Howard et al. (30), and the SCZ-PGS was created from summary statistics obtained from Ripke et
232 al. (31). The NEURO, GAD7, and PHQ9 PGSs were all based on individual level data from the UKB
233 (29,32). Ambiguous SNPs (alleles A/T or C/G), trivial SNPs (showed no variation across UKB)
234 and SNPs with a minor allele frequency (MAF) < 0.01 were all excluded. We used the LDAK
235 software (33) with the BLD-LDAK heritability model (34), where contribution of a SNP depends
236 on MAF, LD and functional annotations. PGS construction was performed with LDAK-Bolt-
237 Predict for individual-level data as well as LDAK-BayesR-SS for summary statistics, and was
238 limited to SNPs that overlapped between cohort genotype, UKB reference panel and GWAS
239 summary statistics. Finally, we converted all PGSs to z-scores for interpretation purposes.

240

241 **Statistical analyses**

242 ***Twin heritability***

243 Twin heritability (h^2_{TWIN}) was estimated by fitting structural equation models that
244 decomposed variance in the outcome measures into additive genetic (A), common-
245 environmental (C) and unique-environmental variance (E) as well as with models that only
246 estimated the A and E components. These models are based on the assumptions that
247 Monozygotic (MZ) and Dizygotic (DZ) twin pairs share common environmental effects to the
248 same extent and that MZ twins share 100% of their segregating alleles, while DZ twins share
249 50% of their segregating alleles. Thus, the additive genetic effects are shared with correlation
250 equal to 1 between MZ pairs and correlation 0.5 between DZ pairs. Analyses were initially
251 performed using only same sex twin pairs and were then repeated including DZ pairs with
252 different sexes in addition to same sex twin pairs. Due to the case/control design (i.e., binary
253 traits as outcome measures), we used the liability threshold model, which assumes a latent
254 bivariate normal distribution of the observed dichotomous variables (35,36). Model fit was
255 assessed by likelihood ratio tests (LRT) and Akaike's information criteria (AIC). All twin models
256 included sex and age as covariates. Twin heritability was analysed with the mets R-package (37).

257

258 ***PGS prediction of anxiety and depression outcomes***

259 To determine effect sizes of PGSs in predicting each of the outcomes based on prescription
260 data (Combined anxiety and depression, Anxiety-only, Depression-only, Medication-only) or
261 diagnosis groups (Combined depression and anxiety diagnoses, anxiety diagnosis, depression
262 diagnosis), we used logistic regression. Effect sizes are presented as adjusted odds ratios (OR)
263 per *SD* PGS, with 95% confidence intervals (95% CI) for each outcome. Pseudo- R^2 (Nagelkerke
264 R^2) was estimated for the full model (all covariates including PGS) and the base model (not
265 including PGS). The latter included sex, age, zygosity (to correct for clustering of family
266 members), the first 20 ancestral principal components (to control for population stratification),
267 and cohort (STAGE, YATSS) as covariates. Proportion of predicted variance was calculated as the
268 difference between the two pseudo- R^2 estimates (ΔR^2). We also calculated area under the
269 Receiver operating characteristics curve (AUC) between the base model and the full model
270 including the best performing PGS.

271 We next included all PGSs in one regression model to assess the ability of each score in
272 predicting the outcomes while controlling for the other PGSs, and evaluated the ΔR^2 to assess
273 how much variance in outcomes could be predicted when all genetic indices were included in
274 the same model. Collinearity diagnostics showed that all variables had a variance inflation factor
275 and tolerance statistic well below 10 and above 0.1, respectively, indicating no significant
276 multicollinearity.

277 To describe associations across the PGS distribution with each outcome, we first selected
278 the PGSs that had the overall strongest association with the outcomes according to their OR and
279 p -value, and divided the sample in deciles based on their PGS. Using logistic regression, we
280 computed the association between each outcome and the highest PGS decile compared with the
281 remaining 80% of the sample (leaving out the bottom 10%). The same analysis was performed
282 for the lowest decile (leaving out the top 10%). These analyses inform on how groups with
283 extreme scores compare with those that have scores closer to the mean. To assess the

284 incremental increase in association between PGS and each outcome across deciles, separate
285 regression analyses were performed for each decile using the lowest as reference.

286 All *p*-values were corrected for multiple comparisons using the Benjamini-Hochberg
287 procedure (38) for False Discovery Rate (FDR < .05).

288

289 **Results**

290 **Sample characteristics**

291 Data on drug prescription were retrieved for 13699 individuals, where genotype
292 information was available for 12792 participants (see Table 1 for sample characteristics). Due to
293 missing data for sex and age, the final sample for PGS-predictions using regression models with
294 covariates included 12558 individuals, whereas twin heritability analyses were based on 1986
295 complete MZ-pairs and 1809 DZ-pairs. The control group for analyses of prescription-based
296 outcomes include all individuals without any prescriptions of the target drugs, while analyses of
297 diagnostically defined outcomes included those without drugs or diagnoses in the control group
298 (see supplemental material for the exact *n* in each analysis).

299 To compare patterns of prescriptions across outcome groups, we computed the proportion
300 of individuals in each group that were prescribed medications from the drug classes N06AA-AB,
301 N06AC-AX, benzodiazepines, antihistamines and Buspirone/Propranolol/Pregabalin
302 (BusProPre) (Fig. 1). In the Anxiety-only category, drugs from the class antihistamines were
303 most frequently prescribed, followed by N06AA-AB and benzodiazepines. In contrast, the
304 Depression-only group had the lowest proportion of prescriptions from the benzodiazepine
305 class compared to any of the other groups. Instead, N06AA-AB was the most commonly
306 prescribed drug class for this group followed by N06AC-AX. The Combined anxiety and
307 depression group had high prescription rates of drugs from the classes N06AA-AB and
308 antihistamines as well as benzodiazepines and N06AC-AX. Notably, individuals in the Combined
309 symptom category were on average prescribed drugs from more drug classes (2.89) compared
310 to any of the other outcome groups (1.28-1.88). The Medication-only group had the lowest rates

311 of prescriptions (1.28) with antihistamines being the most frequently prescribed, followed by
312 N06AA-AB and BusProPre. These results indicate that the prescription text that was used for
313 categorizing individuals into the outcome groups was associated with different treatment
314 decisions.

315 To assess diagnoses of anxiety and depressive disorders, we retrieved data from the
316 National Patient Registry. Out of the 1029 participants with an ICD code associated with these
317 disorders, 379 had only a depression diagnosis, 283 had only an anxiety diagnosis, and 367 had
318 combined depression and anxiety diagnoses. The group with combined anxiety and depression
319 diagnoses consisted of 173 individuals that had both a depression- and an anxiety-related ICD
320 code, 40 individuals with an F41.2 (mixed anxiety and depressive disorder) diagnosis, 50
321 individuals with F41.2 and an anxiety ICD code, 27 individuals with F41.2 and a depression ICD
322 code, and 77 individuals with F41.2 plus a depression and an anxiety ICD code. As expected, the
323 number of individuals with diagnoses were fewer than the number of individuals with
324 prescriptions, as most individuals receiving prescriptions from primary care are not referred to
325 a specialist that enters a diagnosis in the Swedish patient registry.

326

327 **Twin-based heritability of anxiety and depression**

328 The additive genetic influence on having been prescribed medication for combined anxiety
329 and depression was $h^2_{\text{TWIN}} = 0.79$ (95% CI = 0.71-0.86). Lower additive genetic effects were
330 found for having been prescribed medication for Anxiety-only ($h^2_{\text{TWIN}} = 0.41$, 95% CI = 0.23-
331 0.60) or Depression-only ($h^2_{\text{TWIN}} = 0.50$, 95% CI = 0.26-0.75). Further, having been prescribed
332 the same drugs, but without an indication of anxiety or depressive symptoms, resulted in a
333 heritability estimate of $h^2_{\text{TWIN}} = 0.29$ (95% CI = 0.17-0.40). See supplementary Table S1 for twin-
334 model estimates.

335

336

337

338 **Prediction of anxiety and depression from PGSs**

339 ***Regression models with single PGS predictors***

340 Figure 2 shows which PGSs that were significantly associated with the different outcomes,
341 and the strength of associations in terms of OR per *SD* PGS. When modelled as individual
342 predictors, 27 out of the 42 PGSs evaluated (36 from the PGI repository and 6 scores computed
343 for the purpose of this study) showed a significant increase in predicting drugs prescribed for
344 Combined anxiety and depression compared with the base model (base model $R^2 = .041$, AUC =
345 .632). Out of these 27 PGSs, the PGS for depressive symptoms from the PGI repository (DEP-
346 PGS) was the strongest predictor ($\Delta R^2 = .031$, $\Delta AUC = .044$, OR = 1.53, 95% CI = 1.43-1.63)
347 followed by the PGS for major depressive disorder (MDD-PGS) computed from Wray et al. (19)
348 using LDAK ($\Delta R^2 = .020$, $\Delta AUC = .032$, OR = 1.39, 95% CI = 1.30-1.49), PGS for Subjective
349 Wellbeing (SWB-PGS; $\Delta R^2 = .018$, $\Delta AUC = .028$, OR = 0.73, 95% CI = 0.68-0.78), Lifetime Anxiety
350 Disorder (LAD-PGS) computed with LDAK ($\Delta R^2 = .015$, $\Delta AUC = .022$, OR = 1.33, 95% CI = 1.25-
351 1.42), PGS for Self-rated Health ($\Delta R^2 = .014$, $\Delta AUC = .021$, OR = 0.75, 95% CI = 0.70-0.80), and
352 PGS for neuroticism computed with LDAK ($\Delta R^2 = .013$, $\Delta AUC = .020$, OR = 1.30, 95% CI = 1.22-
353 1.39). The pattern of results was similar for the other outcomes, with DEP-PGS being the best or
354 second-best predictor, but the predictive performance of PGSs was markedly reduced as
355 indicated by lower R^2 values and lower ORs per *SD* PGS (Tables S3-S4 and Figure 2). The mean
356 value of DEP-PGS (*z*-scores) in the Combined anxiety and depression group (mean = 0.33) was
357 almost double the mean value in the Depression-only (mean = 0.17) and Anxiety-only (mean =
358 0.16) groups. For comparison, mean values were 0.09 in Medication-only, and -0.08 in the non-
359 medicated control group. One-way ANOVA [$F(4, 12787) = 54.63$, $p < 2e-16$] followed by post-hoc
360 tests, showed that DEP-PGS was on average significantly higher in each outcome group
361 (Combined anxiety and depression, Anxiety-only, Depression-only, Medication-only) compared
362 with the non-medicated control group. However, the Combined anxiety and depression group
363 also had significantly higher mean DEP-PGS as compared to the other outcome groups,

364 indicating that this is a disorder combination with higher polygenic load than anxiety or
365 depression alone (see Supplemental Table S2 for results of post-hoc tests).

366 **Clinical Diagnoses Regressed on Individual PGSs.** To validate case classifications based
367 on drug prescriptions, the regression analyses with PGSs as individual predictors were repeated,
368 but this time with the clinical diagnosis groups as outcomes. For the combined depression and
369 anxiety diagnoses group (base model $R^2 = .047$, $AUC = .667$), DEP-PGS was the strongest
370 predictor ($\Delta R^2 = .036$, $\Delta AUC = .051$, $OR = 1.70$, $95\% CI = 1.53-1.90$) followed by SWB-PGS ($\Delta R^2 =$
371 $.030$, $\Delta AUC = .048$, $OR = 0.61$, $95\% CI = 0.55-0.68$) and MDD-PGS ($\Delta R^2 = .026$, $\Delta AUC = .038$, $OR =$
372 1.59 , $95\% CI = 1.43-1.77$). When predicting the probability of having an anxiety diagnosis (base
373 model $R^2 = .032$, $AUC = .644$), LAD-PGS ($\Delta R^2 = .013$, $\Delta AUC = .022$, $OR = 1.41$, $95\% CI = 1.25-1.60$),
374 DEP-PGS ($\Delta R^2 = .013$, $\Delta AUC = .016$, $OR = 1.40$, $95\% CI = 1.23-1.58$) and MDD-PGS ($\Delta R^2 = .012$,
375 $\Delta AUC = .018$, $OR = 1.39$, $95\% CI = 1.23-1.57$) emerged as the top predictors. For the depression
376 diagnosis group (base model $R^2 = .026$, $AUC = .631$), DEP-PGS ($\Delta R^2 = .015$, $\Delta AUC = .028$, $OR =$
377 1.41 , $95\% CI = 1.27-1.57$), MDD-PGS ($\Delta R^2 = .015$, $\Delta AUC = .022$, $OR = 1.40$, $95\% CI = 1.26-1.55$)
378 and SWB-PGS ($\Delta R^2 = .014$, $\Delta AUC = .029$, $OR = 0.71$, $95\% CI = 0.64-0.79$) were the PGSs with the
379 strongest predictive performance (see suppl. Tables S5-S6 for OR , R^2 , N , and p -values for PGSs
380 predicting ICD diagnoses outcomes). DEP-PGS had the overall highest accuracy and predicted
381 more variation in the combined anxiety and depression diagnoses group compared with those
382 having only one of these diagnoses, which is consistent with results from the regression analyses
383 with symptom categories defined by drug prescription (see Figure 3). Hence, subsequent
384 analyses include only prescription-based symptom categories as outcomes, since they include
385 more cases than the diagnostically defined groups.

386 ***Regression models with multiple PGS predictors***

387 In a single regression model containing all 42 PGSs simultaneously (base model $R^2 = .041$,
388 $AUC = .632$), only DEP-PGS ($OR = 1.23$, $95\% CI = 1.12-1.35$), SCZ-PGS ($OR = 1.18$, $95\% CI = 1.10-$
389 1.27), and MDD-PGS ($OR = 1.14$, $95\% CI = 1.06-1.24$) remained significantly associated with
390 drug prescription for Combined anxiety and depression ($\Delta R^2 = .057$, $\Delta AUC = .071$). When

391 predicting prescriptions for Anxiety-only (base model $R^2 = .023$, AUC = .605), again using all 42
392 PGSs ($\Delta R^2 = .034$, $\Delta AUC = .057$), the only significant predictors were SelfHealth-PGS (OR = 0.800,
393 95% CI = 0.72–0.89) and SCZ-PGS (OR = 1.15, 95% CI = 1.05–1.25). When predicting drug
394 prescription for the Depression-only group ($\Delta R^2 = .031$, $\Delta AUC = .046$) and the Medication-only
395 group ($\Delta R^2 = .017$, $\Delta AUC = .025$), no PGS-predictor survived the correction for multiple
396 comparisons (see suppl. Tables S7-S8 for R^2 , OR and p -values). These results indicate that using
397 multiple PGSs in the same model improves prediction compared to using individual PGSs, but
398 that only a few PGSs have a unique contribution. Also, SCZ-PGS seem to have a unique
399 contribution to the genetic influence on the Combined anxiety and depression and Anxiety-only
400 categories although not being among the top 5 predictors in the regression models using single
401 PGSs.

402 To check for possible confounding of zygosity, the sample was split by kinship and all
403 regression analyses were repeated on the subsamples, with no substantial difference in the
404 pattern of results compared to findings based on whole-sample analyses (see suppl. Tables S9-
405 S16 for regression model estimates on split-half samples with no kinship).

406

407 ***Outcome associations across the PGS distribution***

408 We next wanted to know how extremely high or low PGSs predict drug prescription, as this
409 could indicate whether scores could be useful to identify groups of vulnerable individuals. The
410 highest and lowest deciles of DEP-PGS, the overall best performing genetic index, were
411 compared with the middle 80% of the sample to estimate ORs. Individuals in the top 10% had
412 greater odds of being prescribed medication for Combined anxiety and depressive symptoms
413 (OR = 2.02, CI95% = 1.67-2.42), while those in the bottom 10% had a decreased risk (OR = 0.37,
414 CI95% = 0.27–0.51). Hence, individuals with a PGS in one of the extreme ends of the polygenic
415 continuum carry genetic risk or resilience compared to the rest of the distribution (see
416 regression model estimates for all outcomes in suppl. Table S17).

417 To evaluate whether polygenic risk increased linearly across deciles in the distribution, we
418 computed the OR for each decile compared to the lowest decile. We found a cumulative increase
419 in OR with each decile for DEP-PGS (Figure 4 and suppl. Table S18). These results confirm to
420 expectations from an additive infinitesimal model. The largest OR was found when comparing
421 the lowest and highest deciles of the DEP-PGS (OR = 5.35, 95% CI = 3.78-7.73) in predicting
422 prescription-based symptoms of Combined anxiety and depression.

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

Discussion

445 Using polygenic scores and classical twin models, we investigated genetic influences on
446 prescription of antidepressant and anxiolytic drugs for combined anxiety and depression
447 relative to indications of anxiety or depressive symptoms only. Heritability was 79% for
448 combined anxiety and depression, which was larger than for anxiety or depression alone, and is
449 on par with heritability estimates for schizophrenia (39) and bipolar disorder (40). Combined
450 anxiety and depression was also the outcome most strongly associated with PGSs, indicating that
451 SNP-based prediction concurred with twin-based heritability estimates. These results were
452 corroborated by PGSs more accurately predicting combined clinical depression and anxiety
453 diagnoses compared with those having only a depression or an anxiety diagnosis. Thus, the
454 results from two complementary methods to evaluate genetic influence, and two different case
455 classification approaches, indicate a stronger genetic influence on the Combined symptom
456 category than on anxiety or depressive symptoms alone.

457

458 It is well-known that the combination of anxiety and depressive symptoms is more
459 impairing and difficult to treat than each symptom category alone (7–9). Despite this knowledge,
460 the aetiology of this phenotype combination is poorly understood, and our study represents one
461 of the few attempts made to investigate its genetic basis. There is evidence that the shared
462 genetic component between anxiety and depression is substantially larger than the unique
463 contributions to any of these phenotypes on their own. Large scale GWASs have found robust
464 genetic correlations in the range of 80-95% (16,17), with 99% of risk variants for anxiety also
465 influencing depression and 73% of risk variants for depression also conferring liability to
466 anxiety (21). A conclusion from these findings is that the genetic influence on anxiety and
467 depression is best explained by a common genetic factor. Accordingly, the fraction of unique
468 variants that influence each phenotype could, when combined, only represent a small portion of
469 the increase in genetic liability between the Combined anxiety and depression outcome
470 compared to Anxiety- or Depression-only outcomes. An important consideration is that the large

471 genetic overlap between anxiety and depression has been estimated in GWASs employing
472 minimal phenotyping approaches that do not consider phenotypic heterogeneity (18). Recent
473 findings based on more refined phenotyping showed that MDD with comorbid anxiety was twice
474 as heritable compared to a broadly defined depression phenotype (41), indicating that there
475 may be unique subsets of genetic variants associated with certain disorder subtypes not
476 captured by previous GWASs. Thus, performing a large scale GWASs of the Combined anxiety
477 and depression symptom category could be of value, as it would probably increase the predictive
478 power of PGS predictions and help to tease out whether loci associated with this phenotype
479 combination differs from MDD or anxiety disorders alone.

480
481 In line with the reported large genetic correlations between anxiety and depression
482 (16,17,21), PGS for depressive symptoms predicted Anxiety-only to the same extent as
483 Depression-only. The same pattern emerged for the PGS for lifetime anxiety diagnosis (LAD-
484 PGS) that did not predict anxiety better than depression. PGSs for psychiatric disorders (anxiety,
485 depression, schizophrenia, and ADHD) were however better at predicting anxiety, depression
486 and their combination than were PGSs for physical disorders, body length or consumption of
487 alcohol or marijuana. PGSs for subjective wellbeing and cognitive measures in turn predicted
488 resilience. When controlling for all PGSs, the PGS for schizophrenia emerged as a significant
489 predictor for the Anxiety-only and Combined symptom categories, suggesting that this PGS
490 includes unique risk variants common to several disorders.

491
492 The finding of a distinction between the genetic contribution to combined anxiety and
493 depressive symptoms relative to their isolated manifestations could reflect a more general
494 genetic liability for psychopathology. In a meta-analysis across eight disorders, the Cross
495 Disorder Group of the Psychiatric Genomics Consortium found 109 pleiotropic loci associated
496 with two or more disorders (42), which extends previous results of shared common variant risk
497 across schizophrenia, MDD, bipolar disorder, anxiety disorders, and ADHD (43). Thus, the high

498 degree of genetic overlap among psychiatric disorders suggests that clinical classifications of
499 discrete disorder categories do not reflect distinct underlying processes at the genetic level. A
500 dimensional account of psychopathology has suggested that most common psychiatric disorders
501 are unified by a single transdiagnostic dimension representing lesser-to-greater severity of
502 psychopathology, referred to as the p-factor (44). Combined anxiety and depression represent
503 greater severity than anxiety or depression alone, and the stronger genetic influence on the
504 Combined anxiety and depression outcome could be a result of a genetic factor that makes
505 individuals prone to developing psychiatric illness in general (45). Extending this line of thought
506 to other psychiatric diagnoses, it could be predicted that the combination of any two diagnostic
507 or symptom categories would be associated with greater heritability than each diagnosis in
508 isolation. This hypothesis could be tested in future research.

509
510 Increasing the predictive performance of PGSs is important for risk stratification. We
511 employed AUC estimates to index how well PGSs discriminated between participants with or
512 without depression and anxiety. Participants with combined depression and anxiety determined
513 from prescription data were distinguished from participants without depression or anxiety with
514 an AUC of 68% (i.e., 18% above chance level of 50%) based on DEP-PGS, sex, age and ancestral
515 principal components. The DEP-PGS by itself contributed 4.4% to the overall classification
516 accuracy of the model. When Combined depression and anxiety was defined by ICD diagnoses
517 instead of from prescription data, the AUC was 72% (5.1% unique contribution by DEP-PGS). An
518 AUC of 70% is generally considered fair (46) and a 4-5% increase in overall accuracy solely
519 based on one polygenic score is an important improvement in predictive performance, but
520 questionable for the purpose of risk screening in the general population. To determine a cut-off
521 in terms of AUC for when predictive factors should be implemented in screening and preventive
522 treatment efforts is complex and depends on factors such as patient benefits, costs for the health
523 care system and eventual risks associated with the intervention. For comparison, population
524 screening for adverse childhood events, a well-known social risk factor for psychiatric disorders

525 (47–49) is already underway in the USA where individuals with high scores on an adverse
526 childhood events inventory are referred for health interventions (50). Adverse childhood event
527 scores have been shown to predict anxiety with an AUC ranging from 54% to 59%, and
528 depression with an AUC between 57% and 62% depending on whether adverse childhood
529 events were assessed prospectively or retrospectively (51) which underscores that even modest
530 AUCs can justify interventions if the patient benefits are judged to be large enough. Thus, if PGSs
531 predicting anxiety and depression in the future also can be shown to predict responses to
532 preventive interventions, they could be useful in guiding treatment decisions to improve patient
533 health. We further foresee that PGSs are likely to complement other features in panels of
534 prognostic markers as their predictive performance will increase.

535

536 The study had limitations. Depression related PGSs were based on larger discovery samples
537 than anxiety-related scores, which impacts the results, as the out-of-sample predictive
538 performance of a PGS is dependent on the definition of the phenotype and size of the discovery
539 sample (20). Therefore, predictive performance will likely increase with larger samples and
540 combined with more refined phenotyping. Outcomes were based on symptom categories and
541 treated as life-time events. Consequently, we do not know if individuals' anxiety and depression
542 co-occurred or whether they were separated in time in the group with combined anxiety and
543 depressive symptoms. In either case, our results point to the increased genetic propensity of
544 having been prescribed drugs for combined anxiety and depressive symptoms or having been
545 diagnosed with both disorders in a clinical setting.

546

547 In conclusion, we report larger genetic influence on combined anxiety and depressive
548 symptoms than on either symptom category alone. A tentative explanation could be that
549 depression and anxiety can be described by one latent variable and that increasing severity
550 along this latent variable is associated with increased genetic liability.

551

552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579

Acknowledgments and Disclosures

This research was supported by grants from the Swedish Research Council (2018-01322) and the Bank of Sweden Tercentenary Foundation (P20-0125). The computations and data handling were enabled by resources provided by the National Academic Infrastructure for Supercomputing in Sweden (NAISS) and the Swedish National Infrastructure for Computing (SNIC) at Uppsala Multidisciplinary Center for Advanced Computational Science (UPPMAX) partially funded by the Swedish Research Council through grant agreements no. 2022-06725 and no. 2018-05973.

Preliminary analyses of the data reported here have been presented as abstract/poster at conferences.

Henrik Larsson reports receiving grants from Shire Pharmaceuticals; personal fees from and serving as a speaker for Medice, Shire/Takeda Pharmaceuticals and Evolan Pharma AB; and sponsorship for a conference on attention-deficit/hyperactivity disorder from Shire/Takeda Pharmaceuticals and Evolan Pharma AB, all outside the submitted work. Henrik Larsson is editor-in-chief of JCPP Advances. No other authors report financial interests or potential conflicts of interest.

Author contributions

F.Å. designed the study. F.T. and J.R. performed the behavioral genetics analyses and ran the regression models, F.Å. contributed to interpretation of results. D.S. and X.Z. computed PGSs based on GWAS summary statistics. F.T. and F.Å. wrote the first draft. All authors substantially revised the manuscript. All authors have read and approved the manuscript.

580

References

- 581 1. Bandelow B, Michaelis S. Epidemiology of anxiety disorders in the 21st century. *Dialogues*
582 *Clin Neurosci*. 2015;17(3):327–35.
- 583 2. Lim GY, Tam WW, Lu Y, Ho CS, Zhang MW, Ho RC. Prevalence of Depression in the
584 Community from 30 Countries between 1994 and 2014 /692/699/476/1414 /692/499
585 article. *Sci Rep* [Internet]. 2018;8(1):1–10. Available from:
586 <http://dx.doi.org/10.1038/s41598-018-21243-x>
- 587 3. Kessler RC, Gruber M, Hettema JM, Hwang I, Sampson N, Yonkers KA. Co-morbid major
588 depression and generalized anxiety disorders in the National Comorbidity Survey follow-
589 up. *Psychol Med*. 2008 Mar;38(3):365–74.
- 590 4. Hirschfeld RMA. The comorbidity of major depression and anxiety disorders: Recognition
591 and management in primary care. *Prim Care Companion J Clin Psychiatry*.
592 2001;3(6):244–54.
- 593 5. Mineka S, Watson D, Clark LA. Comorbidity of anxiety and unipolar mood disorders. *Annu*
594 *Rev Psychol*. 1998;49(February 1998):377–412.
- 595 6. Olfson M, Fireman B, Weissman MM, Leon AC, Sheehan D, Kathol RG, et al. Mental
596 disorders and disability among patients in a primary care group practice. *American*
597 *Journal of Psychiatry* [Internet]. 1997;154(12):1734–40. Available from:
598 [http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed7&NEWS=N&AN=2](http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed7&NEWS=N&AN=27516592)
599 [7516592](http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed7&NEWS=N&AN=27516592)
- 600 7. Dold M, Bartova L, Souery D, Mendlewicz J, Serretti A, Porcelli S, et al. Clinical
601 characteristics and treatment outcomes of patients with major depressive disorder and
602 comorbid anxiety disorders - results from a European multicenter study. *J Psychiatr Res*
603 [Internet]. 2017;91:1–13. Available from:
604 <http://dx.doi.org/10.1016/j.jpsychires.2017.02.020>
- 605 8. Fava M, Rush AJ, Alpert JE, Ph D, Balasubramani GK, Ph D, et al. Difference in Treatment
606 Outcome in Outpatients With Anxious Versus Nonanxious Depression : A STAR * D
607 Report. 2008;(March):342–51.
- 608 9. Tiller JWG. Depression and anxiety. *Medical Journal of Australia*. 2012;1(October):28–32.
- 609 10. Kendall KM, Van Assche E, Andlauer TFM, Choi KW, Luykx JJ, Schulte EC, et al. The genetic
610 basis of major depression. *Psychol Med* [Internet]. 2021 Oct 8;51(13):2217–30. Available
611 from:
612 [https://www.cambridge.org/core/product/identifier/S0033291721000441/type/journal](https://www.cambridge.org/core/product/identifier/S0033291721000441/type/journal_article)
613 [_article](https://www.cambridge.org/core/product/identifier/S0033291721000441/type/journal_article)
- 614 11. Smoller JW. The Genetics of Stress-Related Disorders: PTSD, Depression, and Anxiety
615 Disorders. *Neuropsychopharmacology*. 2016;41(1):297–319.
- 616 12. Middeldorp CM, Cath DC, Van Dyck R, Boomsma DI. The co-morbidity of anxiety and
617 depression in the perspective of genetic epidemiology. A review of twin and family
618 studies. *Psychol Med*. 2005;35(5):611–24.
- 619 13. Hettema JM. What is the genetic relationship between anxiety and depression? Vol. 148,
620 *American Journal of Medical Genetics, Part C: Seminars in Medical Genetics*. 2008. p. 140–
621 6.
- 622 14. Guffanti G, Gameroff MJ, Warner V, Talati A, Glatt CE, Wickramaratne P, et al. Heritability
623 of major depressive and comorbid anxiety disorders in multi-generational families at high
624 risk for depression. *American Journal of Medical Genetics, Part B: Neuropsychiatric*
625 *Genetics*. 2016 Dec 1;171(8):1072–9.
- 626 15. Torkamani A, Wineinger NE, Topol EJ. The personal and clinical utility of polygenic risk
627 scores. *Nat Rev Genet* [Internet]. 2018;19(9):581–90. Available from:
628 <http://dx.doi.org/10.1038/s41576-018-0018-x>
- 629 16. Levey DF, Gelernter J, Polimanti R, Zhou H, Cheng Z, Aslan M, et al. Reproducible Genetic
630 Risk Loci for Anxiety: Results From ~200,000 Participants in the Million Veteran
631 Program. *Am J Psychiatry*. 2020;177(3):223–32.

- 632 17. Purves KL, Coleman JRI, Meier SM, Rayner C, Davis KAS, Cheesman R, et al. A major role
633 for common genetic variation in anxiety disorders. *Mol Psychiatry* [Internet].
634 2020;25(12):3292–303. Available from: <http://dx.doi.org/10.1038/s41380-019-0559-1>
635 18. Cai N, Revez JA, Adams MJ, Andlauer TFM, Breen G, Byrne EM, et al. Minimal phenotyping
636 yields genome-wide association signals of low specificity for major depression. *Nat Genet*
637 [Internet]. Available from: <http://dx.doi.org/10.1038/s41588-020-0594-5>
638 19. Wray NR, Ripke S, Mattheisen M, Trzaskowski M, Byrne EM, Abdellaoui A, et al. Genome-
639 wide association analyses identify 44 risk variants and refine the genetic architecture of
640 major depression. *Nat Genet*. 2018;50(5):668–81.
641 20. Mitchell BL, Thorp JG, Wu Y, Campos AI, Nyholt DR, Gordon SD, et al. Polygenic Risk
642 Scores Derived From Varying Definitions of Depression and Risk of Depression. *JAMA*
643 *Psychiatry*. 2021 Oct;78(10):1152–60.
644 21. Als TD, Kurki MI, Grove J, Voloudakis G, Therrien K, Tasanko E, et al. Depression
645 pathophysiology, risk prediction of recurrence and comorbid psychiatric disorders using
646 genome-wide analyses. *Nat Med*. 2023 Jul 1;29(7):1832–44.
647 22. Valderas JM, Starfield B, Sibbald B, Salisbury C, Roland M. Defining comorbidity:
648 Implications for understanding health and health services. *Ann Fam Med*. 2009;7(4):357–
649 63.
650 23. Becker J, Burik CAP, Goldman G, Wang N, Jayashankar H, Bennett M, et al. Resource profile
651 and user guide of the Polygenic Index Repository. *Nat Hum Behav*. 2021;
652 24. Lichtenstein P, Sullivan PF, Cnattingius S, Gatz M, Johansson S, Carlström E, et al. The
653 Swedish Twin Registry in the third millennium: An update. *Twin Research and Human*
654 *Genetics*. 2006;9(6):875–82.
655 25. Zagai U, Lichtenstein P, Pedersen NL, Magnusson PKE. The Swedish Twin Registry:
656 Content and Management as a Research Infrastructure. *Twin Research and Human*
657 *Genetics*. 2019;22(6):672–80.
658 26. Donahue KL, D’Onofrio BM, Lichtenstein P, Långström N. Testing Putative Causal
659 Associations of Risk Factors for Early Intercourse in the Study of Twin Adults: Genes and
660 Environment (STAGE). *Arch Sex Behav*. 2013 Jan 23;42(1):35–44.
661 27. Socialstyrelsen. National Prescribed Drug Register. . 2020 [cited 2023 Feb 27].
662 Socialstyrelsen. Available from: [https://www.socialstyrelsen.se/en/statistics-and-](https://www.socialstyrelsen.se/en/statistics-and-data/registers/national-prescribed-drug-register/)
663 [data/registers/national-prescribed-drug-register/](https://www.socialstyrelsen.se/en/statistics-and-data/registers/national-prescribed-drug-register/)
664 28. WHO. WHO. Collaborating Centre for Drug Statistics Methodology [Internet]. 2021 [cited
665 2023 Feb 27]; Available from: <https://www.whocc.no/>
666 29. UK Biobank. Vol. 7, Protocol No: UKBB-PROT-09-06.PROT-09-06. 2007. p. 1–112 UK
667 Biobank: Protocol for a large-scale prospective epidemiological resource. Available from:
668 <http://www.ukbiobank.ac.uk/wp-content/uploads/2011/11/UK-Biobank-Protocol.pdf>.
669 30. Howard DM, Adams MJ, Clarke TK, Hafferty JD, Gibson J, Shiralil M, et al. Genome-wide
670 meta-analysis of depression identifies 102 independent variants and highlights the
671 importance of the prefrontal brain regions. *Nat Neurosci* [Internet]. 2019;22(3):343–52.
672 Available from: <http://dx.doi.org/10.1038/s41593-018-0326-7>
673 31. Ripke S, Walters JTR, O’Donovan MC, Consortium TSWG of the PG. Mapping genomic loci
674 prioritises genes and implicates synaptic biology in schizophrenia. *medRxiv* [Internet].
675 2020 Jan 1;2020.09.12.20192922. Available from:
676 <http://medrxiv.org/content/early/2020/09/13/2020.09.12.20192922.abstract>
677 32. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK Biobank: An Open
678 Access Resource for Identifying the Causes of a Wide Range of Complex Diseases of
679 Middle and Old Age. *PLoS Med*. 2015;12(3):1–10.
680 33. Speed D, Holmes J, Balding DJ. Evaluating and improving heritability models using
681 summary statistics. *Nat Genet*. 2020 Apr 23;52(4):458–62.
682 34. Zhang Q, Privé F, Vilhjálmsson B, Speed D. Improved genetic prediction of complex traits
683 from individual-level data or summary statistics. *Nat Commun* [Internet]. 2021;12(1):1–
684 9. Available from: <http://dx.doi.org/10.1038/s41467-021-24485-y>

- 685 35. Falconer DS. The inheritance of liability to certain diseases, estimated from the incidence
686 among relatives. *Ann Hum Genet.* 1965;29.
- 687 36. Neale MC, Maes HH. *Methodology for Genetic Studies of Twins and Families.* Dordrecht:
688 Kluwer Academics. 2004;
- 689 37. Holst KK, Scheike T. *mets* (R package). Version 0.2.8. . URL: [http://cran.r-](http://cran.r-project.org/web/packages/mets/)
690 [project.org/web/packages/mets/](http://cran.r-project.org/web/packages/mets/).
- 691 38. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful
692 Approach to Multiple Testing. *Journal of the Royal Statistical Society: Series B*
693 (Methodological). 1995;57(1):289–300.
- 694 39. Hilker R, Helenius D, Fagerlund B, Skytthe A, Christensen K, Werge TM, et al. Heritability
695 of Schizophrenia and Schizophrenia Spectrum Based on the Nationwide Danish Twin
696 Register. *Biol Psychiatry.* 2018 Mar;83(6):492–8.
- 697 40. Gordovez FJA, McMahon FJ. The genetics of bipolar disorder. *Mol Psychiatry.* 2020
698 Mar;25(3):544–59.
- 699 41. Nguyen TD, Harder A, Xiong Y, Kowalec K, Hägg S, Cai N, et al. Genetic heterogeneity and
700 subtypes of major depression. *Mol Psychiatry* [Internet]. 2022 Mar 8;27(3):1667–75.
701 Available from: <https://www.nature.com/articles/s41380-021-01413-6>
- 702 42. Lee PH, Anttila V, Won H, Feng YCA, Rosenthal J, Zhu Z, et al. Genomic Relationships,
703 Novel Loci, and Pleiotropic Mechanisms across Eight Psychiatric Disorders. *Cell*
704 [Internet]. 2019 Dec;179(7):1469-1482.e11. Available from:
705 <https://linkinghub.elsevier.com/retrieve/pii/S0092867419312760>
- 706 43. Anttila V, Bulik-Sullivan B, Finucane HK, Walters RK, Bras J, Duncan L, et al. Analysis of
707 shared heritability in common disorders of the brain. *Science* (1979). 2018 Jun
708 22;360(6395).
- 709 44. Caspi A, Houts RM, Belsky DW, Goldman-Mellor SJ, Harrington H, Israel S, et al. The p
710 factor: One general psychopathology factor in the structure of psychiatric disorders?
711 *Clinical Psychological Science.* 2014 Mar 1;2(2):119–37.
- 712 45. Waszczuk MA, Eaton NR, Krueger RF, Shackman AJ, Waldman ID, Zald DH, et al.
713 Redefining Phenotypes to Advance Psychiatric Genetics: Implications From Hierarchical
714 Taxonomy of Psychopathology. *J Abnorm Psychol.* 2019;
- 715 46. Rice ME, Harris GT. Comparing effect sizes in follow-up studies: ROC area, Cohen’s d, and
716 r. *Law Hum Behav.* 2005 Oct;29(5):615–20.
- 717 47. Hughes K, Bellis MA, Hardcastle KA, Sethi D, Butchart A, Mikton C, et al. The effect of
718 multiple adverse childhood experiences on health: a systematic review and meta-analysis.
719 *Lancet Public Health.* 2017 Aug 1;2(8):e356–66.
- 720 48. Reuben A, Moffitt TE, Caspi A, Belsky DW, Harrington H, Schroeder F, et al. Lest we forget:
721 comparing retrospective and prospective assessments of adverse childhood experiences
722 in the prediction of adult health. *J Child Psychol Psychiatry.* 2016 Oct 1;57(10):1103–12.
- 723 49. Felitti VJ, Anda RF, Nordenberg D, Williamson DF, Spitz AM, Edwards V, et al. Relationship
724 of childhood abuse and household dysfunction to many of the leading causes of death in
725 adults: The adverse childhood experiences (ACE) study. *Am J Prev Med.* 1998
726 May;14(4):245–58.
- 727 50. Centers for Disease Control and Prevention.
728 <https://www.cdc.gov/violenceprevention/aces/ace-brfss.html>. 2024. Behavioral Risk
729 Factor Surveillance System Survey ACE Data, 2009-2021. .
- 730 51. Baldwin JR, Caspi A, Meehan AJ, Ambler A, Arseneault L, Fisher HL, et al. Population vs
731 Individual Prediction of Poor Health from Results of Adverse Childhood Experiences
732 Screening. *JAMA Pediatr.* 2021 Apr 1;175(4):385–93.
- 733
- 734
- 735

736 **Table 1.** Sample Characteristics.

737

Variable	Description	N	%, \bar{X} (SD, range)	N06AA-AB	N06AC-AX	Benzo	Antihis	BusProPre	\bar{X} drugs prescribed
Sample	Total	13699	100%	2425	1140	1064	2133	620	0.54
Sex	Female	7939	58.00%	1830	788	780	1664	458	0.70
	Male	5087	37.10%	595	301	284	469	162	0.36
Age	Age at final data extraction (2023)	13026	51.69 (7.87, 38-85)	-	-	-	-	-	-
Zygosity	Complete MZ	3972	28.99%	695	273	297	655	159	0.52
	Complete DZ same sex	1732	12.64%	305	128	143	262	86	0.53
	Complete DZ diff. Sex	1886	13.77%	253	145	111	223	67	0.42
	No kinship	6109	44.60%	1172	594	513	993	308	0.59
Outcomes	Combined Anxiety and Depression	1054	7.07%	978	591	499	784	190	2.89
	Anxiety only	744	4.99%	357	134	307	500	99	1.88
	Depression only	511	3.43%	448	205	44	126	38	1.68
	Medication only	1630	10.93%	642	210	214	723	293	1.28

738

739


740

741

742

Note. BusProPre = Buspirone or Propranolol or Pregabalin; Benzo = Benzodiazepines; Antihis = Antihistamines; N06AA = non-selective monoamine reuptake inhibitors; N06AB = selective serotonin reuptake inhibitors; N06AC-AX = monoamine oxidase inhibitors (non-selective), monoamine oxidase A inhibitors, other antidepressants. No kinship = individuals without sibling in data set due to missing genotype information.

743 **Figure 1.** Proportion of outcome groups with prescription divided on by drug class.
744



745
746
747 Note: N06AA-AB = non-selective monoamine reuptake inhibitors, selective serotonin reuptake
748 inhibitors (SSRIs); N06AC-AX = monoamine oxidase inhibitors (non-selective), monoamine oxidase A
749 inhibitors, other antidepressants (which include certain selective serotonin and noradrenaline reuptake
750 inhibitors as well as other drugs); Benzo = benzodiazepine derivatives; BusProPre = Buspirone,
751 Propranolol, Pregabalin. Drug classifications are based on their Anatomical Therapeutic Chemical
752 code (ATC).
753

Figure 2. Adjusted OR per SD increase in PGSs predicting prescription-based outcomes. Error bars represent 95% CI.






Figure 3. Genetic liability for anxiety and depression outcomes. (A) Twin heritability for each outcome (AE-model), error bars represent 95% CI. (B) Accuracy (ΔR^2) of depressive symptoms PGS (DEP-PGS) from the Polygenic Index Repository in predicting each outcome above the baseline model.



756
757
758
759
760
761
762

Figure 4. Genetic risk across the PGS distribution. OR per *SD* PGS with 95% CI for each decile of Depressive symptoms PGS (DEP-PGS) compared with the first decile.



763
764
765
766